Multiple System Atrophy (MSA) Market to Reach USD 2.38 Billion by 2034

Pune, India - December 2025 - The global Multiple System Atrophy (MSA) Market, valued at USD 1.34 billion in 2024, is projected to reach USD 2.38 billion by 2034, growing at a 6.0% CAGR (2025-2034), according to Exactitude Consultancy. Rising recognition of atypical parkinsonism, improvements in autonomic testing, and growing clinical efforts targeting alpha-synuclein pathology are fueling market expansion.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71911

Market Summary
The Multiple System Atrophy Market is gaining momentum as this rare, rapidly progressive neurodegenerative disorder-characterized by autonomic dysfunction, parkinsonism, and cerebellar ataxia-becomes increasingly detectable through advances in neurological imaging and autonomic function testing.
MSA has two primary forms:
• MSA-P (Parkinsonian subtype)
• MSA-C (Cerebellar subtype)
Both forms involve misfolded alpha-synuclein accumulation in oligodendrocytes, leading to widespread neurodegeneration. Key symptoms include orthostatic hypotension, urinary dysfunction, impaired balance, tremor, rigidity, and speech/swallowing difficulties.

There is currently no disease-modifying therapy, and management focuses on symptomatic control using:
• Levodopa (limited response)
• Droxidopa & midodrine for orthostatic hypotension
• Bladder relaxants & catheters for urinary dysfunction
• Physical therapy & assistive mobility devices
• Riluzole, rasagiline, and synuclein-targeted agents under investigation
Improved diagnostic pathways such as MRI, autonomic neurophysiology testing, cardiovascular reflex testing, and advanced PET tracers are contributing to earlier diagnosis.
North America and Europe lead with robust diagnostic networks and clinical research, while Asia-Pacific is the fastest-growing market, driven by better neurology infrastructure and rising awareness of atypical parkinsonism.

Key Takeaways
• 2024 Market Size: USD 1.34 Billion
• 2034 Forecast: USD 2.38 Billion
• CAGR: 6.0% (2025-2034)**
• Autonomic dysfunction treatment driving significant therapy demand
• Growing pipeline targeting alpha-synuclein aggregation
• Asia-Pacific rapidly expanding due to improved neurology care

Market Drivers
• Rising global incidence of Parkinsonian and autonomic disorders
• Improved understanding of alpha-synuclein pathophysiology
• Expansion of autonomic testing facilities and advanced neuroimaging
• Growing investment in rare neurodegenerative disease R&D
• Increased patient referral to specialized movement disorder centers

Segmentation Snapshot
By Disease Type
• MSA-P (Parkinsonian) - Largest Segment
• MSA-C (Cerebellar)

By Treatment Type
• Dopaminergic Agents (Levodopa, Amantadine)
• Autonomic Symptom Therapies
o Droxidopa
o Midodrine
o Fludrocortisone
• Bladder Dysfunction Treatments
• Speech & Physical Therapy
• Pipeline Investigational Therapies
o Synuclein-targeted agents
o Neuroprotective molecules
o Immunotherapies

By Diagnosis
• Neurological Examination
• MRI (Hot Cross Bun Sign)
• Autonomic Testing
• Cardiovascular Reflex Testing
• Urodynamic Assessment
• PET & Synuclein Biomarker Research

By End User
• Hospitals
• Neurology Clinics
• Movement Disorder Centers
• Diagnostic Laboratories
• Research Institutions

By Region
• North America (Largest Share)
• Europe
• Asia-Pacific (Fastest Growth)
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/71911/multiple-system-atrophy-msa-market

Recent Developments
• Increased clinical trial activity targeting synuclein aggregation and propagation.
• Rising adoption of droxidopa and midodrine for neurogenic orthostatic hypotension.
• AI-based gait and speech analysis tools enabling earlier detection.
• Improved caregiver-support technologies and tele-neurology platforms.

Expert Quote - Irfan Tamboli, Business Development Executive
"Multiple system atrophy is a rapidly progressive and devastating disorder. Advances in autonomic testing, synuclein biology, and symptomatic care are improving patient outcomes and driving new research momentum."

Conclusion
The Multiple System Atrophy Market is expected to grow steadily through 2034 as diagnostic capabilities improve, supportive therapies advance, and research accelerates toward disease-modifying treatments. Companies investing in synuclein pathology, neuroprotective mechanisms, biomarker diagnostics, and digital neurological assessment tools will play a central role in shaping the market's future.

This report is also available in the following languages : Japanese (多系統萎縮症(MSA)市場), Korean (다발계통위축증(MSA) 시장), Chinese (多系统萎缩症 (MSA) 市场), French (Marché de l'atrophie multisystémique (AMS)), German (Markt für Multisystematrophie (MSA)), and Italian (Mercato dell'atrofia multisistemica (MSA)), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71911

Related Reports

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market
https://exactitudeconsultancy.com/reports/72065/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-market

Spinal Muscular Atrophy Market
https://exactitudeconsultancy.com/reports/72075/spinal-muscular-atrophy-market

Autosomal Dominant Optic Atrophy Market
https://exactitudeconsultancy.com/reports/72222/autosomal-dominant-optic-atrophy-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.